REDWOOD CITY, Calif., March 19, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of multiple Oncotype DX® breast cancer studies at the 9 th European Breast Cancer Conference (EBCC-9), which takes place March 19-21 in Glasgow, Scotland, United Kingdom. New data will include an independently conducted physician survey that underscores the need for broader availability of standard predictive genomic testing, like Oncotype DX, to help better inform chemotherapy treatment decisions in early-stage breast cancer patients in Europe. Additional studies showcasing the unsurpassed volume and consistency of clinical validation, clinical utility and health-economics evidence supporting the use of Oncotype DX will also be presented at the meeting.
"Over the past decade, we have generated more clinical evidence than any company in the world around genomics in breast cancer, and the unmatched body of support specifically for the use of the Oncotype DX breast cancer test is highlighted in the EBCC presentations," said Christer Svedman, M.D., senior director of medical affairs in Europe, Genomic Health. "We will continue to apply world-class science to lead the translation of massive amounts of genomic data into practice-changing results to achieve better standards in treatment planning in breast cancer worldwide."
Physician Survey Reveals Substantial Differences in Chemotherapy Treatment Recommendations, Underscoring the Need for Broader Genomic Testing in Europe to Enable More Informed Decisions
Estrogen receptor (ER) positive breast cancer patients receive hormonal treatment after surgery, but sometimes chemotherapy is also needed. The Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey[i] aims to identify the role of classic pathology criteria that clinicians use in daily practice when recommending adjuvant chemotherapy in ER positive patients. This online survey analyzed responses from 911 physicians representing 52 countries. The results reveal substantial heterogeneity in the criteria used to determine chemotherapy use, suggesting a compelling need for broader use of objective, predictive genomic tests which can help physicians and patients make more informed treatment decisions.